CSA eye drops potentially useful for SEI treatment after AK

Article

Cycloisporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK).

Cyclosporine A (CSA) 1% eye drops could be an effective corticosteroid-sparing agent for treating symptomatic corneal subepithelial infiltrates (SEI) after adenoviral keraconjunctivitis (AK), claims a paper featured in Cornea.

A retrospective case series led by Dr Bennie Jeng, Department of Ophthalmology, University of California, San Francisco, California, USA, included patients with symptomatic corneal SEI occurring after AK from 2 institutions. All patients were resistant to tapering of corticosteroid eye drops prior to administration of CSA drops.

Basic demographic data, involved eyes, duration of symptoms, initial best spectacle-corrected visual acuity (BSCVA), types of corticosteroid administered, clinical course and best spectacle-corrected visual acuity at the final follow-up visit.

Symptomatic SEI after AK, that was resistant to tapering but responsive to corticosteroid eye drops, was found in 12 eyes of 7 patients. The corticosteroid eye drops could be tapered after the administration of CSA eye drops.

It was found that all eyes could generally be maintained on CSA drops for once a day or less. However, the research suggests further study into the use of CSA drops in treating SEI.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.